Regulatory Story
Company AorTech International PLC
Headline Posting of Report & Accounts and Notice of Meeting
Released 13:36 05-Aug-2019
Number 9283H13

RNS Number : 9283H
AorTech International PLC
05 August 2019

5 August 2019


AorTech International plc

("AorTech", the "Company" or the "Group")


Posting of Report & Accounts


Notice of Meeting


 AorTech International plc (AIM: AOR), the biomaterials IP and medical device development company, announces that its Annual Report and Accounts for the year ended 31 March 2019, have been posted to shareholders and are available on the Company's website at


The Annual General Meeting will be held on Monday 19 August 2019 at 11.00 a.m. at the offices of Davidson Chalmers Stewart LLP at 163 Bath Street Glasgow G2 4SQ.


For further information contact:


AorTech International plc                                                            Tel: +44 (0)7730 718296

Bill Brown, Executive Chairman                                                   


Shore Capital                                                                                 Tel: +44 (0)20 7408 4050

Tom Griffiths / David Coaten                                                      



About AorTech:


AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on its behalf by Biomerics LLC in Utah, USA. Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 6 million implants and over 10 years of successful clinical use AorTech polymers are proven in long term life enabling applications.


In addition to continuing to exploit AorTech's Intellectual Property related to the world class biomaterial -

Elast-Eon™, AorTech is now incorporating this material into a number of medical devices of our own design. Elast-Eon™ has first class long term blood contacting properties and as a result, all of the initial products being developed are for the cardio vascular field. Each device is being designed to have improved clinical outcomes over current device technology,eliminating the use of animal sourced material whilst allowing procedures to remain the same, therefore avoiding the need of having to retrain surgeons in new ways of operating.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.